Silperisone: A centrally acting muscle relaxant

CNS Drug Reviews

Volumn 12, Issue 3-4, 2006, Pages 218-235

  Farkas, Sándor ^a  

^a GEDEON RICHTER LTD   (Hungary)

Author keywords

Antispasmodics; Decerebrate rigidity; Muscle relaxants; Organosilicon drugs; Silperisone; Sodium channel blockers; Spasticity; Spinal reflex; Tolperisone; Tremor

Indexed keywords

BACLOFEN; CALCIUM CHANNEL; CARISOPRODOL; CENTRAL MUSCLE RELAXANT; DIAZEPAM; EPERISONE; MEMANTINE; MEPHENESIN; ORGANOSILICON DERIVATIVE; SILPERISONE; SODIUM CHANNEL; SPASMOLYTIC AGENT; TOLPERISONE; UNCLASSIFIED DRUG; ZOXAZOLAMINE;

ATAXIA; CENTRAL NERVOUS SYSTEM DEPRESSION; CLINICAL TRIAL; DECEREBRATION; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; HUMAN; MUSCLE WEAKNESS; NERVE EXCITABILITY; NONHUMAN; PHARMACODYNAMICS; REVIEW; SPASTICITY; SPINAL REFLEX; TREMOR;

ANIMALS; BENZENE DERIVATIVES; HUMANS; MUSCLE RELAXANTS, CENTRAL; PIPERIDINES;

EID: 33845988398     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2006.00218.x     Document Type: Review

References (28)

1. Bains W, Tacke R. Silicon chemistry as a novel source of chemical diversity in drug design. Curr Opin Drug Dis Devel 2003;6:526-543.
2. Bielik N, Farkas S, Kocsis P. Studies on the mechanism of action of RGH-5002, a centrally acting muscle relaxant, using whole cell patch clamp technique. Neurobiology 1997;5:43-45.
3. Düring, T, Koppenhöfer E. Effects of silperisone on the excitation process in Ranvier nodes. Gen Physiol Biophys 2001;20:157-173.
4. Farkas S, Berzsenyi P, Kárpáti E, Kocsis P, Tarnawa I. Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs. J Pharmacol Toxicol Meth 2005;52:264-273.
5. Farkas S, Földeák S, Kárpáti E, et al. Organosilane derivatives, pharmaceutical compositions containing them and process for preparing same. European Patent 1992; EP 0468825 (US 5198446; 1993).
6. Farkas S, Kárpáti E. Electromyographic measurement of the flexor reflex in cats for testing centrally acting muscle relaxants. Pharmacol Res Comm 1988;20(Suppl I):141-142.
7. Farkas S, Kárpáti E. The pharmacology of RGH-5002, a new centrally acting muscle relaxant with a long duration of action and less motor side-effects. Pharmacol Res 1992;25(Suppl 2):25-26.
8. Farkas S, Ono H. Participation of NMDA and non-NMDA excitatory amino acid receptors in the mediation of spinal reflex potentials in rats: An in vivo study. Br J Pharmacol 1995;114:1193-1205.
9. Farkas S, Tarnawa I, Berzsenyi P. Effects of some centrally acting muscle relaxants on spinal root potentials: A comparative study. Neuropharmacology 1989;28:161-173.
10. Fehér M, Juvancz P, Szontágh M. Effect of Mydocalm in the rehabilitation of hemiparesis. Balneol Rehabilit Gyógyfü rdóügy 1985;6:201-205.
11. Gémesi L, Kapás M. High-performance liquid Chromatographic method for the determination of RGH-5002 in human, rabbit and rat plasma. J Pharm Biomed Anal 1996;14:1233-1239.
12. Hinck D, Koppenhöfer E. Tolperisone - A novel modulator of ionic currents in myelinated axons. Gen Physiol Biophys 2001;20:413-429.
13. Ito T, Hori M, Furukawa K. Pharmacological studies of 1-(2, 3-dimethyl-4-methoxyphenyl)-2-methyl-3-(1-pyrrolidinyl)-1-propanone hydrochloride (AD-2239), a centrally acting muscle relaxant. Arch Int Pharmacodyn Ther 1985;275:105-122.
14. Kocsis P, Farkas S, Fodor L, et al. Tolperisone-type drugs inhibit spinal reflexes via blockade of voltagegated sodium and calcium channels. J Pharmacol Exp Ther 2005;315:1237-1246.
15. Kuroiawa Y, Sobue I, Tazaki Y, Nakanishi T, Ohtomo E, Itahara K. Effects of E-0646 on cases of spasticity: A double-blind comparison using tolperisone hydrochloride. Clin Eval 1981;9:391-491.
16. Matsunaga M, Uemura Y, Yonemoto Y, et al. Long-lasting muscle relaxant activity of eperisone hydrochloride after percutaneous administration in rats. Jpn J Pharmacol 1997;73:215-220.
17. Miskolczi P, Vereczkey L, Frenkl R. Gas-liquid chromatographic method for the determination of tolperisone in human plasma: pharmacokinetic and bioavailabiliry studies. J Pharm Biomed Anal 1987;5:695-700.
18. Morikawa K, Oshita M, Yamazaki M. Pharmacological studies of the new centrally acting muscle relaxant 4′-ethyl-2-methyl-3- pyrrolidinopropiophenone hydrochloride. Arzneimitteforschung 1987;37:331-336.
19. Nance PW, Sheremata WA, Lynch SG, et al. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol 1997;54:731-736.
20. Newman PM, Nogues M, Newman PK, Weightman D, Hudson P. Tizanidine in the treatment of spasticity. Eur J Clin Pharmacol 1982;23:31-35.
21. Ochiai T. and Ishida R. Pharmacological studies on 6-amino-2- fluorornethyl-3-(o-tolyl)-4(3H)-quinazoli-none (afloqualone), anew centrally acting muscle relaxant (I). Jpn J Pharmacol 1981;31:491-501.
22. Ono H, Fukuda H, Kudo Y. Mechanisms of depressant action of muscle relaxants on spinal reflexes: Participation of membrane stabilizing action. J Pharmacobiodyn 1984;7:171-176.
23. Pórszász J, Nádor K, Gibiszer-Pórszász K, Barankay T. Pharmacologie einer neuen interneuron-lahmenden Substanz 1-piperidino-2-methyl-3-(p-tolyl)-propan-3-on. Arzneimitteforschung 1961;11:257-260.
24. Pratzel HG, Alken RG, Ramm S. Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful muscle spasm: Results of a prospective placebo-controlled double-blind trial. Pain 1996;67:417-425.
25. Sakitama K, Ozawa Y, Aoto N, Nakamura K, Ishikawa M. Pharmacological properties of NK-433, a new centrally acting muscle relaxant. Eur J Pharmacol 1995;273:47-56.
26. Tacke R, Zilch H. Sila-substitution -a useful strategy for drug design? Endeavour 1986;10:191-197.
27. Tanaka K, Kaneko T, Yamatsu K. Effects of 4′-ethyl-2-methyl-3- piperidinopropiophenone on experimental contracture and spinal cord activities. Folia Pharmacol Japan 1981;77:511-520.
28. Terjéki E, Pátfalusi M, Trafikánt G, Kapás M. Distribution and elimination of RGH-5002 in rats. Acta Physiol Hung 1995;83:143-150.